Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis, inflammatory bowel disease, psoriatic arthritis, and lupus. It also develops VTX002, an oral sphingosine 1 phosphate receptor 1 modulator that has completed phase I clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor for the treatment of systemic inflammatory diseases, such as cardiovascular, hepatic, renal, and rheumatologic diseases. In addition, the company develops CNS-penetrant NLRP3 inhibitors. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in Encinitas, California.
IPO Year: 2021
Exchange: NASDAQ
Website: ventyxbio.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/12/2024 | $12.00 | Perform → Outperform | Oppenheimer |
| 3/12/2024 | $7.00 → $16.00 | Equal Weight → Overweight | Wells Fargo |
| 11/7/2023 | $46.00 → $6.00 | Overweight → Equal-Weight | Morgan Stanley |
| 11/7/2023 | Outperform → Perform | Oppenheimer | |
| 11/7/2023 | Buy → Neutral | H.C. Wainwright | |
| 11/7/2023 | $6.00 | Buy → Hold | Stifel |
| 11/7/2023 | $77.00 → $8.00 | Overweight → Equal Weight | Wells Fargo |
| 6/14/2023 | $63.00 | Outperform | Credit Suisse |
| 3/21/2023 | $77.00 | Overweight | Wells Fargo |
| 12/19/2022 | $50.00 | Buy | Goldman |
A Phase 2 obesity and cardiometabolic trial of VTX3232 and a Phase 2a trial of VTX3232 in patients with Parkinson's disease are both expected to initiate in H2 2024 A Phase 2 trial of VTX2735 in recurrent pericarditis is expected to initiate in H2 2024 Mark Forman, MD, PhD will join Ventyx as Chief Medical Officer effective August 12, 2024 Cash, cash equivalents and marketable securities of $279.7 million as of June 30, 2024 are expected to fund planned operations into at least the second half of 2026 SAN DIEGO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (NASDAQ:VTYX) ("Ventyx"), a clinical-stage biopharmaceutical company focused on advancing novel oral therapie
SAN DIEGO, May 16, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (NASDAQ:VTYX), ("Ventyx"), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, today announced the appointment of industry veteran Matthew Moore as Chief Operating Officer. "I am excited to welcome Matt to the Ventyx leadership team," said Raju Mohan, Chief Executive Officer. "He brings a wealth of expertise to Ventyx from his multiple decades in the biopharma industry. In his role as COO, Matt will play an important role in driving corporate operations, business development and strategy." "I am excited to
ENCINITAS, Calif., Jan. 12, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (NASDAQ:VTYX) ("Ventyx"), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced the appointment of Allison J. Hulme, Ph.D. and Onaiza Cadoret-Manier to its board of directors. Dr. Hulme and Ms. Cadoret-Manier are both successful executives who each bring a wealth of knowledge from more than 30 years of experience in biotech and pharmaceutical drug development and commercialization. Dr. Allison Hulme currently serves as Chief Executive Officer, President and a board member of Aeo
ENCINITAS, Calif., May 09, 2022 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (NASDAQ:VTYX), ("Ventyx"), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, today announced the appointment of William Sandborn, MD, as President and Chief Medical Officer. "I am delighted to welcome Bill to the Ventyx leadership team," said Raju Mohan, CEO. "In addition to being an accomplished physician, a world-renowned immunologist and an expert in the field of inflammatory bowel disease, Bill has also played a key role in the development of a number of approved therapies in the immunology sp
EFFECT - Ventyx Biosciences, Inc. (0001851194) (Filer)
424B3 - Ventyx Biosciences, Inc. (0001851194) (Filer)
S-3 - Ventyx Biosciences, Inc. (0001851194) (Filer)
10-Q - Ventyx Biosciences, Inc. (0001851194) (Filer)
8-K - Ventyx Biosciences, Inc. (0001851194) (Filer)
D - Ventyx Biosciences, Inc. (0001851194) (Filer)
8-K - Ventyx Biosciences, Inc. (0001851194) (Filer)
8-K - Ventyx Biosciences, Inc. (0001851194) (Filer)
10-Q - Ventyx Biosciences, Inc. (0001851194) (Filer)
8-K - Ventyx Biosciences, Inc. (0001851194) (Filer)
SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (NASDAQ:VTYX) ("Ventyx", "Company"), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that Company executives will participate in the following upcoming investor conferences: •Event: Stifel 2024 Healthcare Conference Location: New York, NY Date: Monday, November 18, 2024 Time: 4:10-4:40 PM ET •Event: Jefferies London Healthcare Conference Location: London, UK Date: Wednesday, November 20, 2024 Time: 8:00-8:25 AM GMT •Event: Piper Sandler Healthcare Conference Location: New York,
Topline results from the Phase 2a trial of VTX3232 in patients with early Parkinson's disease expected in H1 2025 Phase 2 trial of VTX3232 in subjects with obesity and cardiometabolic risk factors expected to initiate by year-end, with topline results anticipated in H2 2025 Phase 2 trial of VTX2735 in patients with recurrent pericarditis expected to initiate by year-end, with topline results anticipated in H2 2025 Cash balance of $274.8M as of September 30, 2024 expected to fund operations into at least H2 2026 SAN DIEGO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (NASDAQ:VTYX) ("Ventyx"), a clinical-stage biopharmaceutical company focused on advancing novel oral therap
SAN DIEGO, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (NASDAQ:VTYX) ("Ventyx"), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that a late-breaking abstract including new long-term extension (LTE) data from the Phase 2 trial of tamuzimod in ulcerative colitis was presented on October 15, 2024 during the United European Gastroenterology (UEG) Week meeting in Vienna, Austria. "We are excited to present the new long-term extension data from the tamuzimod Phase 2 trial in patients with ulcerative colitis at UEG Week," said Raju Mohan, P
SAN DIEGO, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (NASDAQ:VTYX) ("Ventyx"), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that Sanofi has agreed to make a $27 million strategic investment in the Company at an as-converted price of $3.8243 per share of common stock, pursuant to which Sanofi will purchase 70,601 of the Company's Series A non-voting convertible preferred stock, each share of which is initially convertible into 100 shares of common stock. The closing of the transaction is expected to occur on September 23, 2024. "
SAN DIEGO, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (NASDAQ:VTYX) ("Ventyx"), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that the first patient has been dosed in a Phase 2a trial of VTX3232 in patients with early Parkinson's disease. "We are excited to initiate this trial of VTX3232 in patients with early Parkinson's disease," said Mark Forman, MD, PhD, Chief Medical Officer. "There is a compelling body of evidence from the literature suggesting a strong mechanistic rationale for targeting NLRP3-driven neuroinflammation in Pa
SAN DIEGO, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (NASDAQ:VTYX) ("Ventyx"), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that Martin Auster, M.D. has departed from his role as Chief Financial Officer, effective August 30, 2024. Roy Gonzales, CPA, MBA, the Company's SVP of Finance, has assumed the roles of interim Principal Financial Officer and interim Principal Accounting Officer for SEC reporting purposes. The company has initiated a search for a CFO. "Marty has been a valued member of our executive team over these past thr
SAN DIEGO, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (NASDAQ:VTYX) ("Ventyx", "Company"), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that Company executives will participate in the following upcoming investor conferences: Event: 2024 Wells Fargo Healthcare ConferenceLocation: Boston, MADate: Wednesday, September 4, 2024Time: 11:00-11:35 AM ET Event: Morgan Stanley 22nd Annual Global Healthcare ConferenceLocation: New York, NYDate: Friday, September 6, 2024Time: 1:05-1:40 PM ET A webcast of the presentations will b
A Phase 2 obesity and cardiometabolic trial of VTX3232 and a Phase 2a trial of VTX3232 in patients with Parkinson's disease are both expected to initiate in H2 2024 A Phase 2 trial of VTX2735 in recurrent pericarditis is expected to initiate in H2 2024 Mark Forman, MD, PhD will join Ventyx as Chief Medical Officer effective August 12, 2024 Cash, cash equivalents and marketable securities of $279.7 million as of June 30, 2024 are expected to fund planned operations into at least the second half of 2026 SAN DIEGO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (NASDAQ:VTYX) ("Ventyx"), a clinical-stage biopharmaceutical company focused on advancing novel oral therapie
The Phase 2 trial of VTX958 in Crohn's disease did not meet its primary endpoint of change from baseline in mean CDAI score in either VTX958 dose group Both VTX958 dose groups achieved nominal statistical significance on the key secondary endpoint of endoscopic response as measured by SES-CD At this time, Ventyx does not anticipate conducting additional clinical trials of VTX958 with internal resources SAN DIEGO, July 29, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (NASDAQ:VTYX) ("Ventyx"), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced res
VTX3232 demonstrated improvements in body weight, systemic inflammatory biomarkers and cardiometabolic parameters in diet-induced obesity (DIO) mice Additive effects were observed for VTX3232 in combination with the GLP-1 receptor agonist semaglutide across key endpoints compared to semaglutide or VTX3232 alone SAN DIEGO, June 05, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (NASDAQ:VTYX) ("Ventyx"), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced positive preclinical data for its CNS-penetrant NLRP3 inhibitor VTX3232 in murine diet-induced ob
SC 13G/A - Ventyx Biosciences, Inc. (0001851194) (Subject)
SC 13G/A - Ventyx Biosciences, Inc. (0001851194) (Subject)
SC 13G/A - Ventyx Biosciences, Inc. (0001851194) (Subject)
SC 13G/A - Ventyx Biosciences, Inc. (0001851194) (Subject)
SC 13G/A - Ventyx Biosciences, Inc. (0001851194) (Subject)
SC 13D/A - Ventyx Biosciences, Inc. (0001851194) (Subject)
SC 13G - Ventyx Biosciences, Inc. (0001851194) (Subject)
SC 13G - Ventyx Biosciences, Inc. (0001851194) (Subject)
SC 13D/A - Ventyx Biosciences, Inc. (0001851194) (Subject)
SC 13D/A - Ventyx Biosciences, Inc. (0001851194) (Subject)
3 - Ventyx Biosciences, Inc. (0001851194) (Issuer)
4 - Ventyx Biosciences, Inc. (0001851194) (Issuer)
3 - Ventyx Biosciences, Inc. (0001851194) (Issuer)
4 - Ventyx Biosciences, Inc. (0001851194) (Issuer)
4 - Ventyx Biosciences, Inc. (0001851194) (Issuer)
4 - Ventyx Biosciences, Inc. (0001851194) (Issuer)
4 - Ventyx Biosciences, Inc. (0001851194) (Issuer)
4 - Ventyx Biosciences, Inc. (0001851194) (Issuer)
4 - Ventyx Biosciences, Inc. (0001851194) (Issuer)
4 - Ventyx Biosciences, Inc. (0001851194) (Issuer)
Phase 2a trials of CNS-Penetrant NLRP3 Inhibitor VTX3232 to initiate in H2 2024 in patients with early Parkinson's disease and in participants with obesity with certain additional cardiovascular risk factors Cash, cash equivalents and marketable securities of $302.6 million as of March 31, 2024 are expected to fund planned operations into at least the second half of 2026 Ventyx to host conference call and webcast today at 4:30PM ET SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (NASDAQ:VTYX) ("Ventyx"), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medi
SAN DIEGO, May 02, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (NASDAQ:VTYX), ("Ventyx"), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, today announced that it will report financial results for the first quarter ended March 31, 2024 after market close on May 9, 2024. Company management will host a conference call and webcast beginning at 4:30 p.m. ET/ 1:30 p.m. PT that day to discuss the financial results and highlight recent pipeline and business progress. To participate in the conference call, please dial (800) 343-4849 (U.S.) or (203) 518-9848 (international)
VTX3232 was well-tolerated in the Phase 1 trial with robust target coverage achieved in both plasma and CSF; Ventyx is planning to initiate Phase 2a trials in Parkinson's disease and obesity in H2 2024 Topline Phase 2 data for VTX2735 in CAPS patients establish clinical proof of concept; Ventyx is planning to evaluate VTX2735 in cardiovascular diseases Early Phase 2 open-label extension data continue to support the clinical profile of VTX002 in ulcerative colitis; Ventyx is planning to seek a partner or other nondilutive financing for pivotal Phase 3 trial Based on pipeline reprioritization and recent PIPE financing, Ventyx expects its current cash, cash equivalents and marketable securit
VTX958 225 mg BID and 300 mg BID doses achieved statistical significance on the primary endpoint (PASI 75) and all key secondary endpoints at Week 16 Efficacy results did not meet the internal target to support further development of VTX958 in psoriasis; Ventyx to terminate Phase 2 trials of VTX958 in plaque psoriasis and psoriatic arthritis The ongoing Phase 2 trial of VTX958 in Crohn's disease will continue to enroll; Ventyx intends to conduct an interim efficacy analysis in Q1 2024 Cash, cash equivalents and marketable securities of $300.8M as of September 30, 2023 Ventyx to host conference call and webcast today at 4:30 PM ET SAN DIEGO, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Ventyx Bio
VTX002 60 mg achieved the primary endpoint of clinical remission with a high rate of complete endoscopic remission Both 30 mg and 60 mg doses of VTX002 demonstrated an excellent safety and tolerability profile Ventyx to host conference call and webcast today at 4:30 PM ET SAN DIEGO, Oct. 09, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (NASDAQ:VTYX) ("Ventyx"), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced positive results from the Phase 2 trial of VTX002, a novel oral S1P1 receptor modulator, in patients with moderate-to-severely active ul
Completed enrollment in the Phase 2 trial of VTX002 (S1P1R modulator) in ulcerative colitis and the Phase 2 trial of VTX958 (TYK2 inhibitor) in plaque psoriasis, with topline readouts expected in Q4 2023 Initiated a Phase 1 trial of VTX3232, a novel CNS-penetrant NLRP3 inhibitor, in adult healthy volunteers Cash, cash equivalents and marketable securities of $332.3 million as of June 30, 2023, are expected to fund planned operations into 2025 Ventyx to host conference call and webcast today at 4:30PM ET SAN DIEGO, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (NASDAQ:VTYX) ("Ventyx"), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that
SAN DIEGO, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (NASDAQ:VTYX), ("Ventyx"), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, today announced that it will report financial results for the second quarter ended June 30, 2023 after market close on August 10, 2023. Company management will host a conference call and webcast beginning at 4:30 p.m. ET/ 1:30 p.m. PT that day to discuss the financial results and highlight recent pipeline and business progress. To participate in the conference call, please dial (800) 225-9448 (U.S.) or (203) 518-9708 (internat
Phase 2 trials of VTX958 (TYK2 inhibitor) are ongoing in plaque psoriasis, Crohn's disease and psoriatic arthritis, with topline data in plaque psoriasis expected in Q4 2023 The Phase 2 trial of VTX002 (S1P1R modulator) in ulcerative colitis is progressing, with topline data expected in H2 2023 Cash, cash equivalents and marketable securities of $376.9 million as of March 31, 2023, are expected to fund planned operations into 2025 Ventyx to host conference call and webcast today at 4:30PM ET ENCINITAS, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (NASDAQ:VTYX) ("Ventyx"), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that addr
ENCINITAS, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (NASDAQ:VTYX), ("Ventyx"), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, today announced that it will report financial results for the first quarter ended March 31, 2023 after market close on May 11, 2023. Company management will host a conference call and webcast beginning at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and highlight recent pipeline and business progress. To participate in the conference call, please dial (800) 225-9448 (U.S.) or (203) 518-9708 (int
Phase 2 trials of VTX958 (TYK2 inhibitor) are ongoing in plaque psoriasis, Crohn's disease and psoriatic arthritis, with topline Phase 2 data in plaque psoriasis expected in Q4 2023 The Phase 2 trial of VTX002 (S1P1R modulator) in ulcerative colitis (UC) is on track to complete enrollment by mid-2023, with topline data expected in H2 2023 Initiated a Phase 2 proof-of-mechanism trial of VTX2735 (peripheral NLRP3 inhibitor) in patients with cryopyrin-associated periodic syndrome (CAPS) Cash, cash equivalents and marketable securities of $356.6 million at the end of 2022 plus an additional $48.4 million in net proceeds raised in Q1 2023 under our "At-the-market" (ATM) program are expected t
Oppenheimer upgraded Ventyx Biosciences from Perform to Outperform and set a new price target of $12.00
Wells Fargo upgraded Ventyx Biosciences from Equal Weight to Overweight and set a new price target of $16.00 from $7.00 previously
Morgan Stanley downgraded Ventyx Biosciences from Overweight to Equal-Weight and set a new price target of $6.00 from $46.00 previously
Oppenheimer downgraded Ventyx Biosciences from Outperform to Perform
H.C. Wainwright downgraded Ventyx Biosciences from Buy to Neutral
Stifel downgraded Ventyx Biosciences from Buy to Hold and set a new price target of $6.00
Wells Fargo downgraded Ventyx Biosciences from Overweight to Equal Weight and set a new price target of $8.00 from $77.00 previously
Credit Suisse resumed coverage of Ventyx Biosciences with a rating of Outperform and set a new price target of $63.00
Wells Fargo initiated coverage of Ventyx Biosciences with a rating of Overweight and set a new price target of $77.00
Goldman initiated coverage of Ventyx Biosciences with a rating of Buy and set a new price target of $50.00
HC Wainwright & Co. analyst Emily Bodnar reiterates Ventyx Biosciences (NASDAQ:VTYX) with a Neutral and maintains $6 price target.
U.S. stocks traded mixed toward the end of trading, with the S&P 500 falling around 0.1% on Thursday. The Dow traded up 0.06% to 38,830.40 while the NASDAQ fell 0.16% to 17,160.31. The S&P 500 also fell, dropping, 0.12% to 5,347.42. . Check This Out: Wall Street’s Most Accurate Analysts Give Their Take On 3 Consumer Stocks Delivering High-Dividend Yields Leading and Lagging SectorsConsumer discretionary shares rose by 0.8% on Thursday. In trading on Thursday, utilities shares fell by 0.8%. Top Headline The J. M. Smucker Company (NYSE:SJM) shares gained around 5% on Thursday after the company posted upbeat quarterly earnings. The company reported a fourth-quarter FY
Shares of G-III Apparel Group, Ltd. (NASDAQ:GIII) fell sharply during Thursday's session after the company reported worse-than-expected quarterly sales results. G-III Apparel Group posted adjusted earnings of 13 cents per share, according to data from Benzinga Pro. The company's quarterly sales came in at $609.747 million, missing market estimates of $616.286 million. G-III Apparel Group shares dipped 13.4% to $27.12 on Thursday. Here are some other stocks moving in today’s mid-day session. Gainers Virax Biolabs Group Limited (NASDAQ:VRAX) shares jumped 139.4% to $2.5390. American Oncology Network, Inc. (NASDAQ:AONC) gained 102% to $4.52. American Oncology Network expanded
Gainers Virax Biolabs Group (NASDAQ:VRAX) shares rose 88.8% to $2.02 during Thursday's regular session. The company's market cap stands at $4.7 million. FibroBiologics (NASDAQ:FBLG) shares rose 45.37% to $9.74. The market value of their outstanding shares is at $318.6 million. Aethlon Medical (NASDAQ:AEMD) stock rose 39.58% to $0.61. The company's market cap stands at $3.1 million. American Oncology Network (NASDAQ:AONC) stock rose 32.96% to $3.0. The market value of their outstanding shares is at $30.6 million. Replimune Group (NASDAQ:REPL) shares rose 29.04% to $7.17. The company's market cap stands at $440.6 million. Co-Diagnostics (NASDAQ:CODX) stock rose 27.18% to $1.31. The marke
U.S. stocks traded mixed midway through trading, with the Dow Jones index gaining around 50 points on Thursday. The Dow traded up 0.14% to 38,860.40 while the NASDAQ fell 0.07% to 17,175.73. The S&P 500 also rose, gaining, 0.01% to 5,354.33. Check This Out: Wall Street’s Most Accurate Analysts Give Their Take On 3 Consumer Stocks Delivering High-Dividend Yields Leading and Lagging SectorsConsumer discretionary shares rose by 0.5% on Thursday. In trading on Thursday, utilities shares fell by 0.5%. Top Headline Lululemon Athletica Inc. (NASDAQ:LULU) reported upbeat financial results for its first quarter and authorized a $1 billion increase in its stock repurchase program on
Oppenheimer analyst Jeff Jones maintains Ventyx Biosciences (NASDAQ:VTYX) with a Outperform and lowers the price target from $12 to $10.
HC Wainwright & Co. analyst Emily Bodnar reiterates Ventyx Biosciences (NASDAQ:VTYX) with a Neutral and maintains $6 price target.
VTX3232 demonstrated improvements in body weight, systemic inflammatory biomarkers and cardiometabolic parameters in diet-induced obesity (DIO) miceAdditive effects were observed for VTX3232 in combination with the GLP-1 receptor agonist semaglutide across key endpoints compared to semaglutide or VTX3232 alone